NASDAQ : ELUT

Elutia Inc — News

$0.95 USD

$0.02 (2.14%)

Volume
49.77K
Average Volume
116.23K
Market Capitalization
$42M
P/E Ratio
0.76
Dividend Yield
0.00%
Price Target
$10.00
Year High
$2.50
Year Low
$0.50
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$2.05
Source Headline
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

globenewswire.com - 2026-07-16 16:05:00

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas, Nevada on June 17–18, 2026.

globenewswire.com - 2026-06-11 16:05:00

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”).

globenewswire.com - 2026-05-18 16:05:00

Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript

Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-14 20:10:46

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunity Strong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestiture Conference call today at 5:00 p.m. ET / 2:00 p.m.

globenewswire.com - 2026-05-14 16:05:00

Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18, 2026.

globenewswire.com - 2026-05-14 16:01:00

Elutia to Present at the 16th Annual LD Micro Invitational May 18th

Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Elutia Inc. (NASDAQ: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy-one of the most significant challenges facing patients and surgeons-through its drug-eluting biomatrix technology designed to support safer, more reliable reconstructive outcomes.

newsfilecorp.com - 2026-05-14 16:01:00

Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026.

globenewswire.com - 2026-04-30 16:05:00

Get ELUT Insider Trade Alerts

ELUT Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$0.00

0 analysts

Last Year

$0.00

0 analysts

All Time

$8.88

4 analysts

ELUT Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2025-09-10 Lake Street Maintain Buy Buy
2025-05-09 Lake Street Maintain Buy Buy
2025-03-07 Cantor Fitzgerald Maintain Overweight Overweight